Notice of Interim Results

RNS Number : 9508C
Avacta Group PLC
23 April 2013
 



 

 

Press Release

23 April 2013

 

Avacta Group plc

("Avacta" or "the Group")

 

Notice of Interim Results

 

Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, will be announcing its Interim Results, for the six month period ended 31 January 2013, on Tuesday, 30 April 2013.

 

An analyst briefing given by Alastair Smith, Chief Executive Officer, and Tim Sykes, Chief Financial Officer, will be held at 09:30 hrs on Tuesday, 30 April 2013 at Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.

 

-Ends-

 

For further information please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Finance Director

Tel:  +44 (0) 844 414 0452 www.avacta.com

Nominated Advisor and Broker

Numis Securities   

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel:  +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Abchurch Communications

Sarah Hollins / Adam Michael / Harriet Rae

harriet.rae@abchurch-group.com

Tel: +44 (0) 207 398 7718

www.abchurch-group.com

 

 

 

Notes to Editors:

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.

Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.

 

The cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.

 

Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

For further information visit www.avacta.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORUUUBRORASUAR
UK 100